The safety of tiotropium--the FDA's conclusions.
Michele
Theresa M
TM
Division of Pulmonary, Allergy, and Rheumatology Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Pinheiro
Simone
S
Iyasu
Solomon
S
D001993:Bronchodilator Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000401:mortality; D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D015201:Meta-Analysis as Topic; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D012602:Scopolamine Derivatives / Q000009:adverse effects* / Q000627:therapeutic use; D000069447:Tiotropium Bromide; D014481:United States; D014486:United States Food and Drug Administration
D001993:Bronchodilator Agents; D012602:Scopolamine Derivatives; D000069447:Tiotropium Bromide